vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and StoneX Group Inc. (SNEX). Click either name above to swap in a different company.
StoneX Group Inc. is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.0× Elanco Animal Health Inc). StoneX Group Inc. runs the higher net margin — 11.6% vs -24.1%, a 35.7% gap on every dollar of revenue. On growth, StoneX Group Inc. posted the faster year-over-year revenue change (81.0% vs 12.2%). Elanco Animal Health Inc produced more free cash flow last quarter ($46.0M vs $-1.3B). Over the past eight quarters, StoneX Group Inc.'s revenue compounded faster (53.5% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
StoneX Group Inc. is an American financial services company. The company operates in six areas: commercial hedging, global payments, securities, physical commodities, foreign exchange and clearing and execution services (CES).
ELAN vs SNEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.2B |
| Net Profit | $-276.0M | $139.0M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 15.4% |
| Net Margin | -24.1% | 11.6% |
| Revenue YoY | 12.2% | 81.0% |
| Net Profit YoY | -3350.0% | 63.3% |
| EPS (diluted) | $-0.55 | $2.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $32.7B | ||
| Q2 25 | $1.2B | $851.2M | ||
| Q1 25 | $1.2B | $820.4M | ||
| Q4 24 | $1.0B | $663.1M | ||
| Q3 24 | $1.0B | $31.1B | ||
| Q2 24 | $1.2B | $571.8M | ||
| Q1 24 | $1.2B | $509.2M |
| Q4 25 | $-276.0M | $139.0M | ||
| Q3 25 | $-34.0M | $85.7M | ||
| Q2 25 | $11.0M | $63.4M | ||
| Q1 25 | $67.0M | $71.7M | ||
| Q4 24 | $-8.0M | $85.1M | ||
| Q3 24 | $364.0M | $76.7M | ||
| Q2 24 | $-50.0M | $61.9M | ||
| Q1 24 | $32.0M | $53.1M |
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | 3.7% | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | 3.0% | ||
| Q2 24 | 58.2% | — | ||
| Q1 24 | 57.3% | — |
| Q4 25 | -22.6% | 15.4% | ||
| Q3 25 | -4.4% | 0.3% | ||
| Q2 25 | 2.0% | -1.3% | ||
| Q1 25 | 5.0% | -1.0% | ||
| Q4 24 | -5.0% | -3.2% | ||
| Q3 24 | 54.3% | -0.0% | ||
| Q2 24 | -2.7% | -4.7% | ||
| Q1 24 | 1.0% | -2.5% |
| Q4 25 | -24.1% | 11.6% | ||
| Q3 25 | -3.0% | 0.3% | ||
| Q2 25 | 0.9% | 7.4% | ||
| Q1 25 | 5.6% | 8.7% | ||
| Q4 24 | -0.8% | 12.8% | ||
| Q3 24 | 35.3% | 0.2% | ||
| Q2 24 | -4.2% | 10.8% | ||
| Q1 24 | 2.7% | 10.4% |
| Q4 25 | $-0.55 | $2.50 | ||
| Q3 25 | $-0.07 | $0.72 | ||
| Q2 25 | $0.02 | $1.22 | ||
| Q1 25 | $0.13 | $1.41 | ||
| Q4 24 | $-0.01 | $1.69 | ||
| Q3 24 | $0.73 | $2.32 | ||
| Q2 24 | $-0.10 | $1.25 | ||
| Q1 24 | $0.06 | $1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $1.6B |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $2.5B |
| Total Assets | $13.4B | $47.8B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $1.6B | ||
| Q3 25 | $505.0M | $1.6B | ||
| Q2 25 | $539.0M | $1.3B | ||
| Q1 25 | $487.0M | $1.3B | ||
| Q4 24 | $468.0M | $1.4B | ||
| Q3 24 | $490.0M | $1.3B | ||
| Q2 24 | $416.0M | $1.2B | ||
| Q1 24 | $345.0M | $1.3B |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $2.5B | ||
| Q3 25 | $6.7B | $2.4B | ||
| Q2 25 | $6.8B | $2.0B | ||
| Q1 25 | $6.4B | $1.9B | ||
| Q4 24 | $6.1B | $1.8B | ||
| Q3 24 | $6.5B | $1.7B | ||
| Q2 24 | $5.9B | $1.6B | ||
| Q1 24 | $6.1B | $1.5B |
| Q4 25 | $13.4B | $47.8B | ||
| Q3 25 | $13.6B | $45.3B | ||
| Q2 25 | $13.7B | $34.3B | ||
| Q1 25 | $12.9B | $31.3B | ||
| Q4 24 | $12.6B | $29.6B | ||
| Q3 24 | $13.3B | $27.5B | ||
| Q2 24 | $13.8B | $25.9B | ||
| Q1 24 | $14.0B | $25.7B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $-1.3B |
| Free Cash FlowOCF − Capex | $46.0M | $-1.3B |
| FCF MarginFCF / Revenue | 4.0% | -106.4% |
| Capex IntensityCapex / Revenue | 5.4% | 1.3% |
| Cash ConversionOCF / Net Profit | — | -9.08× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $3.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $-1.3B | ||
| Q3 25 | $219.0M | $3.5B | ||
| Q2 25 | $237.0M | $1.5B | ||
| Q1 25 | $-4.0M | $-154.5M | ||
| Q4 24 | $177.0M | $-477.8M | ||
| Q3 24 | $162.0M | $192.6M | ||
| Q2 24 | $200.0M | $-622.1M | ||
| Q1 24 | $2.0M | $784.0M |
| Q4 25 | $46.0M | $-1.3B | ||
| Q3 25 | $127.0M | $3.5B | ||
| Q2 25 | $180.0M | $1.5B | ||
| Q1 25 | $-69.0M | $-169.8M | ||
| Q4 24 | $130.0M | $-491.4M | ||
| Q3 24 | $120.0M | $175.9M | ||
| Q2 24 | $166.0M | $-640.5M | ||
| Q1 24 | $-22.0M | $766.6M |
| Q4 25 | 4.0% | -106.4% | ||
| Q3 25 | 11.2% | 10.7% | ||
| Q2 25 | 14.5% | 173.3% | ||
| Q1 25 | -5.8% | -20.7% | ||
| Q4 24 | 12.7% | -74.1% | ||
| Q3 24 | 11.7% | 0.6% | ||
| Q2 24 | 14.0% | -112.0% | ||
| Q1 24 | -1.8% | 150.5% |
| Q4 25 | 5.4% | 1.3% | ||
| Q3 25 | 8.1% | 0.1% | ||
| Q2 25 | 4.6% | 1.9% | ||
| Q1 25 | 5.4% | 1.9% | ||
| Q4 24 | 4.6% | 2.1% | ||
| Q3 24 | 4.1% | 0.1% | ||
| Q2 24 | 2.9% | 3.2% | ||
| Q1 24 | 2.0% | 3.4% |
| Q4 25 | — | -9.08× | ||
| Q3 25 | — | 41.18× | ||
| Q2 25 | 21.55× | 23.52× | ||
| Q1 25 | -0.06× | -2.15× | ||
| Q4 24 | — | -5.61× | ||
| Q3 24 | 0.45× | 2.51× | ||
| Q2 24 | — | -10.05× | ||
| Q1 24 | 0.06× | 14.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
SNEX
Segment breakdown not available.
